Welcome Saara Huoponen
ESiOR Oy gets stronger… We welcome the 10th member of our team! Namely, ISPOR-awarded Saara Huoponen has joined our team as health economic consultant and
11.1.2018
Cost-effectiveness and budget impact analysis including a risk-sharing scheme
Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid
4.12.2017
Akseli Kivioja and Satu Rauhala: stronger service portfolio at ESiOR
Well-known Market Access professionals, Satu Rauhala and Akseli Kivioja, joined ESiOR on August 7th, 2017. Their joint experience is unique: Finnish Pharmaceuticals Pricing Board, pharma industry,
10.8.2017
Paid and unpaid work lost, hidden costs
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a
12.7.2017
RRMS: Considerable differences in the cost effectiveness of treatments
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and
24.2.2017
Professor pharmacoeconomics
Janne Martikainen, PhD (health economics), Adjunct Professor (economic evaluation of pharmaceuticals) in Turku University and one of ESiOR’s health economists and partners is now also
3.1.2017
Development project
Development of business and services portfolio Project’s goals are to innovate and develop new business, support business growth and strengthen national and international competitiveness of
21.12.2016
Nordic RWD conference, meet us there
ESiOR Ltd takes part in Nordic conference on Real World Data – Collaboration between pharma industry and Academia on November 29-30, 2016, in Helsinki. We
21.11.2016
New information on atrial fibrillation and anticoagulation
A large proportion of patients with atrial fibrillation (AF) do not attain the treatment targets with traditional warfarin treatment. As a result, they remain at
18.10.2016
New cost effectiveness information on major depressive disorder
Many patients with major depressive disorder (MDD) do not have adequate response to the first medical treatment or have adverse effects that lead to treatment
18.10.2016
Essential ESiOR: 5 presentations at ISPOR
It is time for celebration. ESiOR will participate in International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress in Vienna for the tenth
17.10.2016
Hallinen T, Soini E, et al.
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus 2016;5:1354. Julkaisuluettelo
12.10.2016
